548 related articles for article (PubMed ID: 22800576)
1. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
2. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
3. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
4. Polymer conjugates as anticancer nanomedicines.
Duncan R
Nat Rev Cancer; 2006 Sep; 6(9):688-701. PubMed ID: 16900224
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice.
Kim JH; Kim YS; Park K; Lee S; Nam HY; Min KH; Jo HG; Park JH; Choi K; Jeong SY; Park RW; Kim IS; Kim K; Kwon IC
J Control Release; 2008 Apr; 127(1):41-9. PubMed ID: 18234388
[TBL] [Abstract][Full Text] [Related]
6. Polymer conjugates: nanosized medicines for treating cancer.
Vicent MJ; Duncan R
Trends Biotechnol; 2006 Jan; 24(1):39-47. PubMed ID: 16307811
[TBL] [Abstract][Full Text] [Related]
7. Toward the next-generation nanomedicines: design of multifunctional multiblock polyurethanes for effective cancer treatment.
Ding M; Song N; He X; Li J; Zhou L; Tan H; Fu Q; Gu Q
ACS Nano; 2013 Mar; 7(3):1918-28. PubMed ID: 23411462
[TBL] [Abstract][Full Text] [Related]
8. A pharmacokinetic model for quantifying the effect of vascular permeability on the choice of drug carrier: a framework for personalized nanomedicine.
Kirtane AR; Siegel RA; Panyam J
J Pharm Sci; 2015 Mar; 104(3):1174-86. PubMed ID: 25583443
[TBL] [Abstract][Full Text] [Related]
9. Nanocarriers as an emerging platform for cancer therapy.
Peer D; Karp JM; Hong S; Farokhzad OC; Margalit R; Langer R
Nat Nanotechnol; 2007 Dec; 2(12):751-60. PubMed ID: 18654426
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring.
Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M
Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832
[TBL] [Abstract][Full Text] [Related]
11. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.
Greco F; Vicent MJ
Adv Drug Deliv Rev; 2009 Nov; 61(13):1203-13. PubMed ID: 19699247
[TBL] [Abstract][Full Text] [Related]
13. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect.
Acharya S; Sahoo SK
Adv Drug Deliv Rev; 2011 Mar; 63(3):170-83. PubMed ID: 20965219
[TBL] [Abstract][Full Text] [Related]
14. Nanotechnology platforms and physiological challenges for cancer therapeutics.
Kim KY
Nanomedicine; 2007 Jun; 3(2):103-10. PubMed ID: 17442621
[TBL] [Abstract][Full Text] [Related]
15. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
Greish K
J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
[TBL] [Abstract][Full Text] [Related]
16. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
17. Polymeric nano-micelles: versatile platform for targeted delivery in cancer.
Mohamed S; Parayath NN; Taurin S; Greish K
Ther Deliv; 2014 Oct; 5(10):1101-21. PubMed ID: 25418269
[TBL] [Abstract][Full Text] [Related]
18. Targeting liposomes toward novel pediatric anticancer therapeutics.
Federman N; Denny CT
Pediatr Res; 2010 May; 67(5):514-9. PubMed ID: 20118828
[TBL] [Abstract][Full Text] [Related]
19. To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?
Danhier F
J Control Release; 2016 Dec; 244(Pt A):108-121. PubMed ID: 27871992
[TBL] [Abstract][Full Text] [Related]
20. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs.
Lukyanov AN; Torchilin VP
Adv Drug Deliv Rev; 2004 May; 56(9):1273-89. PubMed ID: 15109769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
